Literature DB >> 17868749

Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity.

Pierig Lepont1, John T Stickney, Lauren A Foster, Jin-Jun Meng, Robert F Hennigan, Wallace Ip.   

Abstract

Neurofibromatosis type 2 (NF2) is a genetic disorder characterized by the formation of bilateral schwannomas of the eighth cranial nerve. Although the protein product of the NF2 gene (merlin) is a classical tumor suppressor, the mechanism by which merlin suppresses cell proliferation is not fully understood. The availability of isolated tumor cells would facilitate a better understanding of the molecular function of merlin, but primary schwannoma cells obtained from patients grow slowly and do not yield adequate numbers for biochemical analysis. In this study, we have examined the NF2 mutation in HEI-193 cells, an immortalized cell line derived from the schwannoma of an NF2 patient. Previous work showed that the NF2 mutation in HEI-193 cells causes a splicing defect in the NF2 transcript. We have confirmed this result and further identified the resultant protein product as an isoform of merlin previously designated as isoform 3. The level of isoform 3 proteins in HEI-193 cells is comparable to the levels of merlin isoforms 1 and 2 in normal human Schwann cells and several other immortalized cell lines. In contrast to many mutant forms of merlin, isoform 3 is as resistant to proteasomal degradation as isoforms 1 and 2 and can interact with each of these isoforms in vivo. Cell proliferation assays showed that, in NF2(-/-) mouse embryonic fibroblasts, exogenously expressed merlin isoform 3 does exhibit growth suppressive activity although it is significantly lower than that of identically expressed merlin isoform 1. These results indicate that, although HEI-193 cells have undetectable levels of merlin isoforms 1 and 2, they are, in fact, not a merlin-null model because they express the moderately active growth suppressive merlin isoform 3.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17868749      PMCID: PMC2233940          DOI: 10.1016/j.mrfmmm.2007.07.015

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  30 in total

1.  Hierarchy of merlin and ezrin N- and C-terminal domain interactions in homo- and heterotypic associations and their relationship to binding of scaffolding proteins EBP50 and E3KARP.

Authors:  R Nguyen; D Reczek; A Bretscher
Journal:  J Biol Chem       Date:  2000-12-05       Impact factor: 5.157

2.  The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells.

Authors:  Anne-Marie Bashour; J-J Meng; Wallace Ip; Mia MacCollin; Nancy Ratner
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

3.  Multiple transcription initiation sites, alternative splicing, and differential polyadenylation contribute to the complexity of human neurofibromatosis 2 transcripts.

Authors:  Long-Sheng Chang; Elena M Akhmametyeva; Yong Wu; Lingyun Zhu; D Bradley Welling
Journal:  Genomics       Date:  2002-01       Impact factor: 5.736

4.  The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44.

Authors:  H Morrison; L S Sherman; J Legg; F Banine; C Isacke; C A Haipek; D H Gutmann; H Ponta; P Herrlich
Journal:  Genes Dev       Date:  2001-04-15       Impact factor: 11.361

5.  Novel alternatively spliced isoforms of the neurofibromatosis type 2 tumor suppressor are targeted to the nucleus and cytoplasmic granules.

Authors:  B Schmucker; Y Tang; M Kressel
Journal:  Hum Mol Genet       Date:  1999-08       Impact factor: 6.150

6.  Mild familial neurofibromatosis 2 associates with expression of merlin with altered COOH-terminus.

Authors:  M Sainio; J Jääskeläinen; H Pihlaja; O Carpén
Journal:  Neurology       Date:  2000-03-14       Impact factor: 9.910

7.  Interaction between two isoforms of the NF2 tumor suppressor protein, merlin, and between merlin and ezrin, suggests modulation of ERM proteins by merlin.

Authors:  J J Meng; D J Lowrie; H Sun; E Dorsey; P D Pelton; A M Bashour; J Groden; N Ratner; W Ip
Journal:  J Neurosci Res       Date:  2000-11-15       Impact factor: 4.164

8.  Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis.

Authors:  K M M Schulze; C O Hanemann; H W Müller; H Hanenberg
Journal:  Hum Mol Genet       Date:  2002-01-01       Impact factor: 6.150

9.  The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling.

Authors:  R J Shaw; J G Paez; M Curto; A Yaktine; W M Pruitt; I Saotome; J P O'Bryan; V Gupta; N Ratner; C J Der; T Jacks; A I McClatchey
Journal:  Dev Cell       Date:  2001-07       Impact factor: 12.270

Review 10.  Tumorigenesis in neurofibromatosis: new insights and potential therapies.

Authors:  N Reed; D H Gutmann
Journal:  Trends Mol Med       Date:  2001-04       Impact factor: 11.951

View more
  13 in total

1.  Gene therapy with apoptosis-associated speck-like protein, a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivo.

Authors:  Sherif G Ahmed; Ahmed Abdelnabi; Casey A Maguire; Mohamed Doha; Jessica E Sagers; Rebecca M Lewis; Alona Muzikansky; Marco Giovannini; Anat Stemmer-Rachamimov; Konstantina M Stankovic; Giulia Fulci; Gary J Brenner
Journal:  Neuro Oncol       Date:  2019-07-11       Impact factor: 12.300

2.  Mammalian Ste20-like kinase (Mst2) indirectly supports Raf-1/ERK pathway activity via maintenance of protein phosphatase-2A catalytic subunit levels and consequent suppression of inhibitory Raf-1 phosphorylation.

Authors:  Geoffrey K Kilili; John M Kyriakis
Journal:  J Biol Chem       Date:  2010-03-08       Impact factor: 5.157

3.  The Novel Small Molecule Inhibitor, OSU-T315, Suppresses Vestibular Schwannoma and Meningioma Growth by Inhibiting PDK2 Function in the AKT Pathway Activation.

Authors:  M E Mercado-Pimentel; S Igarashi; A M Dunn; M Behbahani; C Miller; C M Read; A Jacob
Journal:  Austin J Med Oncol       Date:  2016-04-21

4.  NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.

Authors:  Maria E R Garcia-Rendueles; Julio C Ricarte-Filho; Brian R Untch; Iňigo Landa; Jeffrey A Knauf; Francesca Voza; Vicki E Smith; Ian Ganly; Barry S Taylor; Yogindra Persaud; Gisele Oler; Yuqiang Fang; Suresh C Jhanwar; Agnes Viale; Adriana Heguy; Kety H Huberman; Filippo Giancotti; Ronald Ghossein; James A Fagin
Journal:  Cancer Discov       Date:  2015-09-10       Impact factor: 39.397

5.  FERM domain phosphoinositide binding targets merlin to the membrane and is essential for its growth-suppressive function.

Authors:  Timmy Mani; Robert F Hennigan; Lauren A Foster; Deborah G Conrady; Andrew B Herr; Wallace Ip
Journal:  Mol Cell Biol       Date:  2011-03-14       Impact factor: 4.272

6.  Inhibiting p21-Activated Kinase Induces Cell Death in Vestibular Schwannoma and Meningioma via Mitotic Catastrophe.

Authors:  Melania Ester Mercado-Pimentel; Craig Miller; Daniela N Rolph; Edrick F Villalobos; Allison M Dunn; Prithvi M Mohan; Suzu Igarashi; Xiangdang Liu; Macken Yrun-Duffy; Neal K Patel; Cecilia M Read; Ross H Francis; Adelina Isabella Lane; Swaroop Murugesh; Abraham Jacob
Journal:  Otol Neurotol       Date:  2017-01       Impact factor: 2.311

7.  A novel alternative splicing isoform of NF2 identified in human Schwann cells.

Authors:  Fang Su; Zhengguang Zhou; Wen Su; Zishu Wang; Qiong Wu
Journal:  Oncol Lett       Date:  2016-06-08       Impact factor: 2.967

8.  Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.

Authors:  Sylwia Ammoun; Marei Caroline Schmid; Joceline Triner; Paul Manley; Clemens Oliver Hanemann
Journal:  Neuro Oncol       Date:  2011-07       Impact factor: 12.300

9.  Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cells.

Authors:  Nesrin Sabha; Karolyn Au; Sameer Agnihotri; Sanjay Singh; Rupinder Mangat; Abhijit Guha; Gelareh Zadeh
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240

10.  Finding minimum gene subsets with heuristic breadth-first search algorithm for robust tumor classification.

Authors:  Shu-Lin Wang; Xue-Ling Li; Jianwen Fang
Journal:  BMC Bioinformatics       Date:  2012-07-25       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.